Cargando…

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers

Immune checkpoint therapy (ICT) can produce durable antitumor responses in various cancer types; however, the responses are not universal, and the predictive biomarkers are urgently needed. Growing evidence points to a link between epigenetic regulation and anti-tumor immunity, while clinical data o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Peng, Huang, Yixuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927217/ https://www.ncbi.nlm.nih.gov/pubmed/33653367 http://dx.doi.org/10.1186/s13045-021-01050-0

Ejemplares similares

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
por: Zhang, Rui, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Haploinsufficiency of KMT2D is sufficient to cause Kabuki syndrome and is compatible with life
por: Luperchio, Teresa Romeo, et al.
Publicado: (2019)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

A pan‐cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness
por: Mei, Song, et al.
Publicado: (2023)

Immunogenomic alterations of head and neck squamous cell carcinomas stratified by smoking status
por: Huang, Yixuan, et al.
Publicado: (2021)

Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
por: Guest, Erin M., et al.
Publicado: (2022)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Lin, Zhihuan, et al.
Publicado: (2020)

An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement– an illustrative report
por: Ray, Debadrita, et al.
Publicado: (2023)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
por: Wu, Yongfeng, et al.
Publicado: (2020)

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

Immune checkpoint inhibitors: friend or foe for osteoporosis
por: Tang, Jun
Publicado: (2023)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy
por: Stemberkova‐Hubackova, Sona, et al.
Publicado: (2022)

Rare Gene Rearrangement t(11;22)(q23;q13)/KMT2A-EP300 in Therapy-related Acute Myeloid Leukemia: A Case Report
por: Kim, Seo Wan, et al.
Publicado: (2022)

CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
por: Ke, Mengying, et al.
Publicado: (2021)

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Liu, Dingxie, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Expression patterns of immune checkpoints in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2020)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
por: Wu, Qiuji, et al.
Publicado: (2020)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Yan, Chi, et al.
Publicado: (2021)

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome
por: Hinai, Adil S.A. Al, et al.
Publicado: (2019)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition
por: Risbjerg, Rasmus Strøm, et al.
Publicado: (2020)

Association of KMT2C/D loss‐of‐function variants with response to immune checkpoint blockades in colorectal cancer
por: Liu, Ruiqi, et al.
Publicado: (2023)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection
por: Bi, Jianping, et al.
Publicado: (2021)

Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non‐small cell lung cancer
por: Khatir, Wassila, et al.
Publicado: (2022)

Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy
por: Chen, Zheng, et al.
Publicado: (2020)

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
por: Tsukita, Yoko, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma
por: Liu, Chuan, et al.
Publicado: (2023)

SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers
por: Wang, Di, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q0bgr1h74nkn0bkbg2lpj7gqc5